Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | SUV39H2 | Q9H5I1 | 14/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21700961 | 1.00 | PIM1 (0.48) | PIM1PIM3PIM2SUV39H2KDM4D | |
| SCHEMBL22382762 | 0.91 | PIM1 (0.48) | PIM1PIM3PIM2SUV39H2KDM4D | |
| SCHEMBL21700742 | 0.91 | PIM1 (0.48) | PIM1PIM3PIM2SUV39H2KDM4D | |
| SCHEMBL29653499 | 0.84 | JAK3 (0.52) | PIM1PIM3PIM2SUV39H2JAK3 | |
| SCHEMBL28777557 | 0.84 | JAK3 (0.52) | PIM1PIM3PIM2SUV39H2JAK3 | |
| SCHEMBL28777563 | 0.84 | JAK3 (0.52) | PIM1PIM3PIM2SUV39H2JAK3 | |
| SCHEMBL2422222 | 0.83 | PIM1 (0.52) | PIM1PIM3PIM2SUV39H2KDM4D | |
| SCHEMBL2422225 | 0.83 | PIM1 (0.52) | PIM1PIM3PIM2SUV39H2KDM4D | |
| SCHEMBL15100929 | 0.83 | PIM1 (0.52) | PIM1PIM3PIM2SUV39H2KDM4D | |
| SCHEMBL30781309 | 0.83 | PIM1 (0.49) | PIM1PIM3PIM2SUV39H2KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | PIM1 4568/4885PIM3 4332/4885PIM2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.